TABLE OF CONTENTS
1 INTRODUCTION 32
1.1 OBJECTIVES OF THE STUDY 32
1.2 MARKET DEFINITION 32
1.3 OVERVIEW 32
1.4 CURRENCY AND PRICING 34
1.5 LIMITATIONS 34
1.6 MARKETS COVERED 34
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 DBMR TRIPOD DATA VALIDATION MODEL 40
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43
2.6 MULTIVARIATE MODELLING 44
2.7 MARKET APPLICATION COVERAGE GRID 45
2.8 PRODUCT LIFELINE CURVE 46
2.9 DBMR MARKET POSITION GRID 47
2.10 VENDOR SHARE ANALYSIS 48
2.11 SECONDARY SOURCES 49
2.12 ASSUMPTIONS 49
3 EXECUTIVE SUMMARY 50
4 PREMIUM INSIGHTS 52
4.1 PESTEL ANALYSIS 55
4.2 PORTER FIVE FORCES 56
4.3 PATENT ANALYSIS 57
4.4 PATIENT FLOW DIAGRAM 58
4.5 KEY PRICING STRATEGIES 59
4.6 FUTURE THERAPIES 60
4.7 KEY PATIENT ENROLLMENT STRATEGIES 61
5 PIPELINE ANALYSIS 62
6 EPIDEMIOLOGY 63
7 INDUSTRY INSIGHTS 64
8 GLOBAL PEMPHIGUS VULGARIS MARKET: REGULATIONS 65
9 MARKET OVERVIEW 68
9.1 DRIVERS 70
9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 70
9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS 70
9.1.3 AWARENESS REGARDING THE DISEASE 71
9.2 RESTRAINTS 71
9.2.1 STRICT REGULATORY GUIDELINES 71
9.2.2 HIGH TREATMENT COSTS 71
9.3 OPPORTUNITIES 72
9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 72
9.3.2 INCREASING HEALTHCARE FACILITIES 72
9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT 73
9.4 CHALLENGES 73
9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS 73
9.4.2 REIMBURSEMENT AND COVERAGE POLICIES 74
10 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 75
10.1 OVERVIEW 76
10.2 TREATMENT 79
10.2.1 MEDICATIONS, BY TYPE 79
10.2.1.1 CORTICOSTEROIDS 80
10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS 80
10.2.1.2.1 AZATHIOPRINE 81
10.2.1.2.2 MYCOPHENALATE MOFETIL 81
10.2.1.2.3 METHOTREXATE 81
10.2.1.2.4 CYCLOPHOSPHAMIDE 81
10.2.1.2.5 MIZORIBINE 81
10.2.1.2.6 OTHERS 81
10.2.1.3 ANTI- INFLAMMATORY AGENTS 81
10.2.1.3.1 DIAMINODYPHENYL SULFONE 82
10.2.1.3.2 TETRACYCLINE 82
10.2.1.3.3 OTHERS 82
10.2.1.4 BIOLOGICS 82
10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN 82
10.2.1.6 ANTIBIOTICS 82
10.2.1.7 ANTIFUNGALS 82
10.2.1.8 ANTIVIRALS 82
10.2.1.9 OTHER MEDICATIONS 82
10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION 82
10.2.2.1 ORAL 83
10.2.2.2 TOPICAL 83
10.2.2.3 PARENTERAL 83
10.2.2.4 OTHERS 83
10.2.3 MEDICATIONS, BY DRUG TYPE 83
10.2.3.1 GENERIC 84
10.2.3.2 BRANDED 84
10.3 DIAGNOSIS 84
10.3.1 SKIN BIOPSY 85
10.3.2 BLOOD TEST 85
10.3.3 ENDOSCOPY 85
11 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 86
11.1 OVERVIEW 87
11.2 ADULTS 90
11.3 GERIATRIC 91
11.4 PEDIATRIC 92
12 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER 93
12.1 OVERVIEW 94
12.2 HOSPITALS 97
12.3 SPECIALTY CLINICS 97
12.4 RESEARCH INSTITUTES 98
12.5 OTHERS 99
13 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 100
13.1 OVERVIEW 101
13.2 HOSPITALS PHARMACY 104
13.3 RETAIL PHARMACY 104
13.4 ONLINE PHARMACY 105
14 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION 106
14.1 OVERVIEW 107
14.2 NORTH AMERICA 112
14.2.1 U.S. 120
14.2.2 CANADA 124
14.2.3 MEXICO 128
14.3 EUROPE 132
14.3.1 GERMANY 141
14.3.2 U.K. 145
14.3.3 FRANCE 149
14.3.4 ITALY 153
14.3.5 SPAIN 157
14.3.6 SWITZERLAND 161
14.3.7 TURKEY 165
14.3.8 RUSSIA 169
14.3.9 BELGIUM 173
14.3.10 NETHERLANDS 177
14.3.11 REST OF EUROPE 180
14.4 ASIA-PACIFIC 181
14.4.1 CHINA 190
14.4.2 INDIA 194
14.4.3 SOUTH KOREA 198
14.4.4 MALAYSIA 202
14.4.5 JAPAN 206
14.4.6 AUSTRALIA 210
14.4.7 SINGAPORE 214
14.4.8 THAILAND 218
14.4.9 INDONESIA 222
14.4.10 PHILIPPINES 226
14.4.11 REST OF ASIA-PACIFIC 229
14.5 SOUTH AMERICA 230
14.5.1 BRAZIL 238
14.5.2 ARGENTINA 242
14.5.3 REST OF SOUTH AMERICA 246
14.6 MIDDLE EAST AND AFRICA 247
14.6.1 SAUDI ARABIA 255
14.6.2 EGYPT 259
14.6.3 U.A.E. 263
14.6.4 SOUTH AFRICA 267
14.6.5 ISRAEL 271
14.6.6 REST OF MIDDLE EAST AND AFRICA 274
15 GLOBAL PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 275
15.1 COMPANY SHARE ANALYSIS: GLOBAL 275
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 276
15.3 COMPANY SHARE ANALYSIS: EUROPE 277
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 278
16 SWOT ANALYSIS 279
17 COMPANY PROFILE 280
17.1 ABBVIE INC. 280
17.1.1 COMPANY SNAPSHOT 280
17.1.2 REVENUE ANALYSIS 280
17.1.3 COMPANY SHARE ANALYSIS 281
17.1.4 PRODUCT PORTFOLIO 281
17.1.5 RECENT DEVELOPMENTS 282
17.2 MERCK & CO., INC., 283
17.2.1 COMPANY SNAPSHOT 283
17.2.2 REVENUE ANALYSIS 283
17.2.3 COMPANY SHARE ANALYSIS 284
17.2.4 PRODUCT PORTFOLIO 284
17.2.5 RECENT DEVELOPMENT 284
17.3 SANOFI 285
17.3.1 COMPANY SNAPSHOT 285
17.3.2 REVENUE ANALYSIS 285
17.3.3 COMPANY SHARE ANALYSIS 286
17.3.4 PRODUCT PORTFOLIO 286
17.3.5 RECENT DEVELOPMENT 286
17.4 REGENERON PHARMACEUTICALS INC. 287
17.4.1 COMPANY SNAPSHOT 287
17.4.2 REVENUE ANALYSIS 287
17.4.3 COMPANY SHARE ANALYSIS 288
17.4.4 PRODUCT PORTFOLIO 288
17.4.5 RECENT DEVELOPMENT 288
17.5 NOVARTIS AG 289
17.5.1 COMPANY SNAPSHOT 289
17.5.2 REVENUE ANALYSIS 289
17.5.3 COMPANY SHARE ANALYSIS 290
17.5.4 PRODUCT PORTFOLIO 290
17.5.5 RECENT DEVELOPMENT 290
17.6 AMGEN INC. 291
17.6.1 COMPANY SNAPSHOT 291
17.6.2 REVENUE ANALYSIS 291
17.6.3 PRODUCT PORTFOLIO 292
17.6.4 RECENT DEVELOPMENTS 292
17.7 ASTRAZENECA 293
17.7.1 COMPANY SNAPSHOT 293
17.7.2 REVENUE ANALYSIS 293
17.7.3 COMPANY SHARE ANALYSIS 294
17.7.4 PRODUCT PORTFOLIO 294
17.7.5 RECENT DEVELOPMENTS 295
17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 296
17.8.1 COMPANY SNAPSHOT 296
17.8.2 REVENUE ANALYSIS 296
17.8.3 PRODUCT PORTFOLIO 297
17.8.4 RECENT DEVELOPMENT 297
17.9 CELLTRION HEALTHCARE CO., LTD 298
17.9.1 COMPANY SNAPSHOT 298
17.9.2 REVENUE ANALYSIS 298
17.9.3 PRODUCT PORTFOLIO 299
17.9.4 RECENT DEVELOPMENTS 299
17.10 F. HOFFMANN- LA ROCHE LTD. 300
17.10.1 COMPANY SNAPSHOT 300
17.10.2 REVENUE ANALYSIS 300
17.10.3 PRODUCT PORTFOLIO 301
17.10.4 RECENT DEVELOPMENT 301
17.11 FRESENIUS KABI AG 302
17.11.1 COMPANY SNAPSHOT 302
17.11.2 REVENUE ANALYSIS 302
17.11.3 PRODUCT PORTFOLIO 303
17.11.4 RECENT DEVELOPMENT 303
17.12 GSK PLC 304
17.12.1 COMPANY SNAPSHOT 304
17.12.2 REVENUE ANALYSIS 304
17.12.3 PRODUCT PORTFOLIO 305
17.12.4 RECENT DEVELOPMENT 305
17.13 JOHNSON & JOHNSON SERVICES, INC. 306
17.13.1 COMPANY SNAPSHOT 306
17.13.2 REVENUE ANALYSIS 306
17.13.3 COMPANY SHARE ANALYSIS 307
17.13.4 PRODUCT PORTFOLIO 307
17.13.5 RECENT DEVELOPMENT 307
17.14 LILLY 308
17.14.1 COMPANY SNAPSHOT 308
17.14.2 REVENUE ANALYSIS 308
17.14.3 PRODUCT PORTFOLIO 309
17.14.4 RECENT DEVELOPMENT 309
17.15 PFIZER INC. 310
17.15.1 COMPANY SNAPSHOT 310
17.15.2 REVENUE ANALYSIS 310
17.15.3 PRODUCT PORTFOLIO 311
17.15.4 RECENT DEVELOPMENT 311
17.16 RAKSHIT DRUGS PVT. LTD 312
17.16.1 COMPANY SNAPSHOT 312
17.16.2 PRODUCT PORTFOLIO 312
17.16.3 RECENT DEVELOPMENT 312
17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD 313
17.17.1 COMPANY SNAPSHOT 313
17.17.2 REVENUE ANALYSIS 313
17.17.3 PRODUCT PORTFOLIO 314
17.17.4 RECENT DEVELOPMENT 314
17.18 ZYDUS GROUP 315
17.18.1 COMPANY SNAPSHOT 315
17.18.2 REVENUE ANALYSIS 315
17.18.3 PRODUCT PORTFOLIO 316
17.18.4 RECENT DEVELOPMENT 316
18 QUESTIONNAIRE 317
19 RELATED REPORTS 319

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.